Company · Private
NewLimit
Epigenetic reprogramming company using machine learning to discover transcription-factor combinations delivered by mRNA, aiming to restore youthful cell function without losing cell identity.
Listing
Private
Ticker
—
Headquarters
South San Francisco, US
Founded
2021
Technology
Epigenetic reprogramming, mRNA delivery
Category
Longevity thesis
Reprogramming only becomes a medicine when factor selection and delivery are engineered together; pairing machine-learned factor discovery with mRNA delivery is the shortest path to a clinic-bound reprogramming product.
Programmes
- Epigenetic reprogramming platformPreclinical
Cell reprogramming therapeutics
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.